Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 3/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | GRB2 | P62993 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 2/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TPH1 | P17752 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22121182 | 1.00 | MME (0.44) | MMEACEDPP4DPP7CTSS | |
| SCHEMBL25831733 | 0.86 | ENPEP (0.41) | MMEGRB2ANPEPENPEPHPGD | |
| SCHEMBL22154816 | 0.86 | ANPEP (0.41) | MMEGRB2ANPEPENPEPHPGD | |
| SCHEMBL27124358 | 0.86 | SLC7A5 (0.53) | MMECTSSCTSKANPEPENPEP | |
| SCHEMBL25818343 | 0.86 | ENPEP (0.41) | MMEGRB2ANPEPENPEPHPGD | |
| SCHEMBL24140474 | 0.86 | SLC7A5 (0.53) | MMECTSSCTSKANPEPENPEP | |
| SCHEMBL22154657 | 0.86 | ANPEP (0.41) | MMEGRB2ANPEPENPEPHPGD | |
| SCHEMBL17728729 | 0.85 | EPHX1 (0.53) | MMEANPEP | |
| SCHEMBL28208789 | 0.85 | EPHX1 (0.53) | MMEANPEP | |
| SCHEMBL17728727 | 0.85 | EPHX1 (0.53) | MMEANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12144864-B2 | Tubulysins and protein-tubulysin conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| CN-118027137-A | Tubulysin and protein-tubulysin conjugates | 里珍纳龙药品有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-113454097-A | Tubulysins and protein-tubulysin conjugates | 里珍纳龙药品有限公司 | 2021-09-28 | — | — | CN | disclosed |
| WO-2020132658-A2 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12144864-B2 | Tubulysins and protein-tubulysin conjugates | SDCBP, TEK, TEKT1 | MME 424/4885ACE 2949/4885DPP4 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.